SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome

Last updated: March 20, 2024
Sponsor: Guy's and St Thomas' NHS Foundation Trust
Overall Status: Active - Recruiting

Phase

N/A

Condition

Head And Neck Cancer

Lung Cancer

Squamous Cell Carcinoma

Treatment

N/A

Clinical Study ID

NCT05400239
SOTO Study 305689
  • Ages > 18
  • All Genders

Study Summary

In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with head and neck squamous cell carcinoma (including oral cavity,oropharynx, paranasal sinuses, hypopharynx or larynx) undergoing curative treatment (primary surgery or radiotherapy) or presenting with recurrent or metastatic cancers
  • Age > 18 years old

Exclusion

Exclusion Criteria:

  • Patients unable to give informed consent e.g. mental disability or vulnerable adults

Study Design

Total Participants: 60
Study Start date:
June 01, 2022
Estimated Completion Date:
June 30, 2025

Study Description

This is a prospective observation study to generate patient-derived organoids from patients' samples to assess treatment response and to correlate with patients' treatment outcomes and to collect preliminary data on the ability of PDOs to predict patients' treatment response and whether their radiosensitivity and chemosensitivity can be correlated with their survival outcome.

Connect with a study center

  • Guys Hospital

    London, SE1 9RT
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.